NEVRO CORP's ticker is NVRO and the CUSIP is 64157F103. A total of 201 filers reported holding NEVRO CORP in Q1 2022. The put-call ratio across all filers is 1.71 and the average weighting 0.1%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $8,697,434 | -1.1% | 452,520 | +30.8% | 0.00% | 0.0% |
| Q2 2023 | $8,795,269 | -43.7% | 345,998 | -20.0% | 0.00% | -66.7% |
| Q1 2023 | $15,627,284 | -13.0% | 432,290 | -4.7% | 0.00% | -25.0% |
| Q4 2022 | $17,953,650 | +18.5% | 453,375 | +39.4% | 0.00% | +33.3% |
| Q3 2022 | $15,154,000 | -1.8% | 325,203 | -7.6% | 0.00% | -25.0% |
| Q2 2022 | $15,433,000 | +31.0% | 352,102 | +116.2% | 0.00% | +100.0% |
| Q1 2022 | $11,782,000 | +66.2% | 162,897 | +86.3% | 0.00% | +100.0% |
| Q4 2021 | $7,090,000 | -87.8% | 87,459 | -82.5% | 0.00% | -91.7% |
| Q3 2021 | $58,189,000 | +902.9% | 499,982 | +1328.5% | 0.01% | +1100.0% |
| Q2 2021 | $5,802,000 | -85.8% | 35,000 | -88.1% | 0.00% | -88.9% |
| Q1 2021 | $40,982,000 | -30.3% | 293,774 | -13.5% | 0.01% | -40.0% |
| Q4 2020 | $58,764,000 | +89.8% | 339,478 | +52.7% | 0.02% | +66.7% |
| Q3 2020 | $30,966,000 | +126.6% | 222,297 | +94.4% | 0.01% | +50.0% |
| Q2 2020 | $13,663,000 | +10.7% | 114,361 | -7.3% | 0.01% | 0.0% |
| Q1 2020 | $12,338,000 | -84.6% | 123,398 | -81.9% | 0.01% | -82.9% |
| Q4 2019 | $79,961,000 | -2.8% | 680,289 | -28.9% | 0.04% | -7.9% |
| Q3 2019 | $82,230,000 | +141.3% | 956,502 | +82.0% | 0.04% | +137.5% |
| Q2 2019 | $34,071,000 | +2.9% | 525,546 | -0.8% | 0.02% | 0.0% |
| Q1 2019 | $33,114,000 | -20.6% | 529,760 | -50.6% | 0.02% | -33.3% |
| Q4 2018 | $41,712,000 | +111.8% | 1,072,576 | +210.5% | 0.02% | +166.7% |
| Q3 2018 | $19,691,000 | +490.6% | 345,454 | +727.3% | 0.01% | +800.0% |
| Q2 2018 | $3,334,000 | +14.9% | 41,759 | +24.7% | 0.00% | 0.0% |
| Q1 2018 | $2,902,000 | -79.1% | 33,488 | -83.4% | 0.00% | -88.9% |
| Q4 2017 | $13,914,000 | -85.8% | 201,534 | -81.3% | 0.01% | -88.0% |
| Q3 2017 | $98,003,000 | +17.6% | 1,078,385 | -3.7% | 0.08% | +7.1% |
| Q2 2017 | $83,324,000 | +65.1% | 1,119,509 | +107.9% | 0.07% | +52.2% |
| Q1 2017 | $50,466,000 | +200.4% | 538,605 | +133.0% | 0.05% | +170.6% |
| Q4 2016 | $16,800,000 | -55.5% | 231,206 | -36.1% | 0.02% | -56.4% |
| Q3 2016 | $37,754,000 | -30.3% | 361,660 | -50.8% | 0.04% | -35.0% |
| Q2 2016 | $54,185,000 | +68.4% | 734,612 | +28.4% | 0.06% | +46.3% |
| Q1 2016 | $32,181,000 | -41.1% | 572,008 | -29.3% | 0.04% | -31.7% |
| Q4 2015 | $54,604,000 | +235.3% | 808,839 | +130.4% | 0.06% | +300.0% |
| Q3 2015 | $16,283,000 | +2291.0% | 350,984 | +2370.7% | 0.02% | +1400.0% |
| Q1 2015 | $681,000 | +179.1% | 14,206 | +125.3% | 0.00% | – |
| Q4 2014 | $244,000 | – | 6,304 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Tiger Eye Capital LLC | 239,122 | $41,392,000 | 8.25% |
| Integral Health Asset Management, LLC | 88,000 | $15,233,000 | 4.53% |
| Iron Triangle Partners LP | 168,761 | $29,213,000 | 3.79% |
| Eos Focused Equity Management, L.P. | 14,002 | $2,424,000 | 2.37% |
| PFM Health Sciences, LP | 311,940 | $53,997,000 | 1.90% |
| Perceptive Advisors | 977,565 | $169,217,000 | 1.82% |
| Rock Springs Capital Management LP | 395,000 | $68,375,000 | 1.45% |
| Lisanti Capital Growth, LLC | 54,302 | $9,400,000 | 1.30% |
| HealthCor Management, L.P. | 156,046 | $27,012,000 | 1.04% |
| FRED ALGER MANAGEMENT, LLC | 2,136,612 | $369,848,000 | 0.96% |